National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Bimekizumab (Bimzelx®). HTA ID: 21052

Bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 15/11/2021
Rapid review completed 07/01/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of bimekizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.